- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
FDA granted Fast Track designation to Allarity Therapeutics' drug, led by CEO Thomas Jensen.
4 reports, 1 independent
Updated Aug 26
Gone quiet
- Reports
- 4
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted Fast Track designation to Allarity Therapeutics' drug, led by CEO Thomas Jensen.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Allarity Therapeutics, led by CEO Thomas Jensen, is advancing its drug stenoparib toward U.S. regulatory approval and holds pending patent applications in China, India, and Japan.Sub-event
Allarity Therapeutics received Fast Track designation from the FDA.1 source
- Allarity Therapeutics secures rights to Eisai's drug; Jensen leads as CEO.
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
- FDA
-
Thomas Jensen
Danish politician
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireAllarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer TARPON SPRINGS, Fla., August 26, 2025 -- Allarity Therapeutics, Inc. (“Allarity” o
- GlobeNewswireAllarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships - Successfully initiated enrollment in advanced Phase 2 ovarian cancer tr
- GlobeNewswireAllarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization TARPON SPRINGS, Fla., July 15, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or t
- Unknown outlet